STOK · ISSUER CIK 1623526
Stoke Therapeutics, Inc.
Between Aug 1, 2026 and Oct 29, 2026, 3 Stoke Therapeutics, Inc. insiders reported $0.00 of open-market purchases and $1.1M of sales on SEC Form 4.
↗3 insiders filed
Original Form 4 filings from Aug 1, 2026 to Oct 29, 2026. 4 of 7 sales were reported under a 10b5-1 plan.
$0.00Insider buying
$1.1MInsider selling
−$1.1MNet open-market
Oct 2, 2026Latest filing
| Ticker | Insider | Type | Owned | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Oct 2, 202617:37 | Oct 2, 2026 | STOK | GENERAL COUNSEL & CORP SEC | S · Sell10b5-1 | $26.33 | −627 | 20,598 | -3% | −$17K | ||
| Oct 2, 202617:35 | Oct 1, 2026 | STOK | CHIEF MEDICAL OFFICER | S · Sell10b5-1 | $26.16 | −1,051 | 19,059 | -5% | −$27K | ||
| Sep 3, 202616:17 | Sep 1, 2026 | STOK | CHIEF MEDICAL OFFICER | S · Sell10b5-1 | $30.67 | −5,545 | 20,110 | -22% | −$170K | ||
| Aug 18, 202620:29 | Aug 18, 2026 | STOK | CHIEF MEDICAL OFFICER | S · Sell | $32.03 | −4,767 | 25,655 | -16% | −$153K | ||
| Aug 18, 202620:29 | Aug 14, 2026 | STOK | CHIEF MEDICAL OFFICER | M · Exercise | — | +10,000 | 30,422 | +49% | — | ||
| Aug 18, 202620:28 | Aug 18, 2026 | STOK | Director | S · Sell | $32.03 | −12,567 | 124,557 | -9% | −$403K | ||
| Aug 18, 202620:28 | Aug 14, 2026 | STOK | Director | M · Exercise | — | +26,250 | 137,124 | +24% | — | ||
| Aug 18, 202620:27 | Aug 18, 2026 | STOK | GENERAL COUNSEL & CORP SEC | S · Sell | $32.03 | −2,861 | 21,225 | -12% | −$92K | ||
| Aug 18, 202620:27 | Aug 14, 2026 | STOK | GENERAL COUNSEL & CORP SEC | M · Exercise | — | +6,000 | 24,086 | +33% | — | ||
| Aug 5, 202616:17 | Aug 3, 2026 | STOK | CHIEF MEDICAL OFFICER | S · Sell10b5-1 | $29.04 | −7,176 | 20,422 | -26% | −$208K |